16.10.2012 - The European Commission gives €6m to a research consortium tackling a severe immune system disorder. „FIGHT HLH“ is led by Swiss Novimmune.
The European Commission wants to dismantle a malicious disease. By spending €6m of FP7 money for research into hemophagocytic lymphohistiocytosis (HLH), it wants to advance knowledge about possible treatment options about this orphan disease. The awardee is a consortium of institutions named FIGHT HLH. Among the institutions are Hospitals in Florence and Rome and Lonza Biologics plc. The consortium leader, however, is based in Switzerland. Novimmune SA from Geneva is the originator of the treatment option in question: NI-0501. This fully human monoclonal antibody is a potent inhibitor of the cytokine IFNγ, Cristina de Min, the company’s Chief Medical Officer, stresses the aim of the collaboration: „The programme is designed to give a clear readout on the ability of the drug to affect disease course.“ Novimmune CEO Jack Barbut adds that he is „delighted to have been selected by the European Commission for such a prestigious grant.“
HLH is caused by an impairment of cytotoxic T cell function that triggers an anomalous activation of the immune system. This activation stems mainly from an dramatic increase in IFNγ levels. NI-0501 targets IFNγ. Novimmune tested the drug in Phase I clinical trials successfully for safety and also demonstrated in animal studies that clearing excess IFNγ with the antibody reverses organ pathology and re-establishes key clinical parameters.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more